A fully human monoclonal antibody that has been found to inhibit interleukin-17A may significantly improve moderate-to-severe plaque psoriasis, according to new phase 2 study data recently released.
Dermal Infusions and Injections Lead to Improved Skin Quality
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
The Weekly Roundup: March 27-31
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
What's Trending in Skin Care: March 2023
Treating Dermatological Conditions by Going Beyond the Skin
2 Clarke Drive Cranbury, NJ 08512